Shockwave Medical

Shockwave Medical Analysis

Shockwave Medical, founded in 2009 and headquartered in the United States, is focused on revolutionizing the interventional treatment of advanced cardiovascular disease. The company's slogan, "Making waves for underserved patients with cardiovascular disease via novel technologies. ⚡🌊", captures its commitment to innovation and patient-centric care.

Shockwave Medical's technology targets calcified plaque, drawing inspiration from 30 years of safety and efficacy in kidney stone treatment. The company's Intravascular Lithotripsy (IVL) family of catheters delivers localized lithotripsy at the site of cardiovascular calcium, enabling gentle balloon dilatation of calcified, stenotic arteries. This approach uses sonic pressure waves to disrupt calcium in hard tissue while leaving soft tissue undisturbed, ensuring a precise and gentle treatment process.

The last recorded investment in Shockwave Medical amounted to $650.00M, in the form of Post-IPO Debt investment on 10 August 2023. This substantial investment underscores the confidence of investors in the company's innovative technology and its potential to address unmet needs in cardiovascular care.

As Shockwave Medical continues to make waves in the biotechnology and healthcare industries, it stands as a compelling example of a company driving impactful innovation at the intersection of technology and patient care.

Stay connected with Shockwave Medical at www.ShockwaveMedical.com and on Twitter @ShockwaveIVL.